loxo-260
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 23, 2022 (NCT05241834)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05241834 | Phase 1 | Mar 23, 2022 | Eli Lilly, Loxo Oncology |
| NCT05225259 | N/A | — | Eli Lilly, Loxo Oncology |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 2 | 2 | 2 | 2022 |
| Loxo Oncology | For profit | 2 | 0 | 2 | 2022 |
2 organizations
Page 1 / 1